Process evaluation and early outcomes of real-world implementation of a pharmacist-driven cabotegravir/rilpivirine long-acting injectable initiative

被引：1
|
作者：
Derrick, Caroline B. [1 ]
Magee, Matthew [2 ]
Tsai, Y. Vivian [3 ]
Pizzuti, Morgan E. [4 ]
Parker, Sarah [2 ]
Lucas, Omar [1 ]
Taylor, Kara [5 ]
Albright, Raeghan [6 ]
Langehans, Briley [7 ]
Schreiber, Danny [8 ]
Guest, Georgia [8 ]
Ahuja, Divya [1 ]
Weissman, Sharon [1 ]
机构：
[1] SC Univ South Carolina, Sch Med Columbia, Prisma Hlth Richland Columbia, Columbia, SC 29208 USA
[2] Univ South Carolina, Sch Med Columbia, Columbia, SC USA
[3] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[4] Prisma Hlth Richland Columbia, Columbia, SC USA
[5] WakeMed Hlth Raleigh, Raleigh, NC USA
[6] Publix Pharm Columbia, Columbia, SC USA
[7] Trident Med Ctr Charleston, Charleston, SC USA
[8] Univ South Carolina, Coll Pharm Columbia, Columbia, SC USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2024年
关键词：
cabotegravir; HIV-1; human immunodeficiency virus; pharmacist; resistance; rilpivirine; VIROLOGICAL FAILURE; HIV-1; INFECTION; RILPIVIRINE;
D O I：
10.1093/ajhp/zxae260
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
    Collins, Lauren F.
    Corbin-Johnson, Della
    Asrat, Meron
    Morton, Zoey P.
    Dance, Kaylin
    Condra, Alton
    Jenkins, Kimberly
    Todd-Turner, Marie
    Sumitani, Jeri
    Smith, Bradley L.
    Armstrong, Wendy S.
    Colasanti, Jonathan A.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09):
  • [42] Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir plus rilpivirine at 12, 24, and 48-weeks
    Nasser, K.
    Valentin, A. -M.
    Ramgopal, M.
    HIV MEDICINE, 2023, 24 : 161 - 162
  • [43] Early Implementation of Long-Acting Injectable Cabotegravir for HIV Prevention in a Safety Net Hospital-based Primary Care Center in US South
    Baker, Dylan
    Collins, Lauren F.
    Cantos, Valeria D.
    Hollenberg, Emma
    Kaplan, Alexander
    Cowan, Terri
    Garcia, Jose
    Lora, Meredith
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2025,
  • [44] Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL): examining health care staff attitudes during a hybrid III implementation-effectiveness trial implementing cabotegravir plus rilpivirine long-acting injectable (CAB plus RPV LA) for people living with HIV (PLHIV)
    Gutner, C.
    Dakhia, S.
    Gill, M.
    Pascual-Bernaldez, M.
    Hernandez, B.
    Rami, A.
    Portilla, J.
    Lutz, T.
    van der Valk, M.
    Florence, E.
    Barnes, N.
    Cooper, O.
    Filipenko, D.
    Hamilton, A.
    Bosse, M.
    Czarnogorski, M.
    HIV MEDICINE, 2021, 22 : 114 - 115
  • [45] Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
    Hodgson, Richard E.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 517 - 524
  • [46] Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics A Nationwide Real-World Study in Japan
    Onitsuka, Toshiaki
    Okada, Tsuyoshi
    Hasegawa, Naomi
    Tsuboi, Takashi
    Iga, Jun-ichi
    Yasui-Furukori, Norio
    Yamada, Naoki
    Hori, Hikaru
    Muraoka, Hiroyuki
    Ohi, Kazutaka
    Ogasawara, Kazuyoshi
    Ochi, Shinichiro
    Takeshima, Masahiro
    Ichihashi, Kayo
    Fukumoto, Kentaro
    Iida, Hitoshi
    Yamada, Hisashi
    Furihata, Ryuji
    Makinodan, Manabu
    Takaesu, Yoshikazu
    Numata, Shusuke
    Komatsu, Hiroshi
    Hishimoto, Akitoyo
    Kido, Mikio
    Atake, Kiyokazu
    Yamagata, Hirotaka
    Kikuchi, Saya
    Hashimoto, Naoki
    Usami, Masahide
    Katsumoto, Eiichi
    Asami, Takeshi
    Kubota, Chika
    Matsumoto, Junya
    Miura, Kenichiro
    Hirano, Yoji
    Watanabe, Koichiro
    Inada, Ken
    Hashimoto, Ryota
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2023, 43 (04) : 365 - 368
  • [47] The implementation of every-2-months cabotegravir and rilpivirine long-acting injections from the perspective of healthcare providers in the German CARLOS cohort, 6-month outcomes
    Scherzer, J.
    Jonsson-Oldenbuettel, C.
    Schneeweiss, S.
    Wyen, C.
    Borch, J.
    Ummard-Berger, K.
    Postel, N.
    Rodriguez, E.
    Gutner, C.
    Dymek, K.
    Westermayer, B.
    Bernhardt, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 40 - 41
  • [48] REAL-WORLD OUTCOMES AND PRACTICE PATTERNS FOR LONG-ACTING INJECTABLE VS. ORAL ANTIPSYCHOTIC AGENTS AMONG HOSPITALIZED PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
    Kane, J. M.
    Rubio, J. M.
    Casciano, J.
    Dotiwala, Z.
    Hansen, R.
    Franzenburg, K. R.
    Philbin, M.
    Thompson, S.
    VALUE IN HEALTH, 2023, 26 (06) : S239 - S239
  • [49] CUSTOMIZE: overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable for HIV treatment in US healthcare settings; final patient and provider data
    Czarnogorski, M.
    Garris, C.
    D'Amico, R.
    Flamm, J.
    Sinclair, G.
    Wohlfeiler, M.
    Mena, L.
    Dalessandro, M.
    McHorney, C.
    Mansukhani, S.
    Williams, W.
    Merrill, D.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 65 - 66
  • [50] POTENTIAL HEALTHCARE RESOURCE USE AND ASSOCIATED COSTS OF EVERY 2-MONTHS INJECTABLE CABOTEGRAVIR plus RILPIVIRINE LONG-ACTING IMPLEMENTATION IN THE SPANISH NHS VS DAILY ORAL HIV TREATMENTS
    Vallejo-Aparicio, L. A.
    Neches, V
    Hernandez Novoa, B.
    Casado, G.
    Jodar, F.
    Pinel, M.
    Callejo-Velasco, D.
    VALUE IN HEALTH, 2022, 25 (12) : S129 - S130
12345